Drug Profile
Bevasiranib
Alternative Names: Bevasiranib sodium; Cand 5Latest Information Update: 10 Feb 2010
Price :
$50
*
At a glance
- Originator Opko Health
- Developer OPKO Health
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in Canada (Intravitreous)
- 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in USA (Intravitreous)
- 08 Dec 2008 OPKO Health completes enrolment in the phase III COBALT trial for Age-related macular degeneration in USA and Canada